European Surgical Research

Original Paper

Pancreatic Carcinoma Cell Lines Reflect Frequency and Variability of Cancer Stem Cell Markers in Clinical Tissue

Bünger S.a · Barow M.a · Thorns C.d · Freitag-Wolf S.g · Danner S.f · Tiede S.b · Pries R.e · Görg S.c · Bruch H.-P.a · Roblick U.J.a · Kruse C.f · Habermann J.K.a

Author affiliations

aLaboratory for Surgical Research, Department of Surgery, bDepartment of Dermatology, Allergology and Venerology and cInstitute of Immunology and Transfusion Medicine, University of Lübeck, dInstitute of Pathology and eENT Department, University Clinic of Schleswig-Holstein, Campus Lübeck, and fFraunhofer Research Institution for Marine Biotechnology, Lübeck, and gInstitute of Medical Informatics and Statistics, Christian-Albrechts-University, Kiel, Germany

Keywords: Cancer stem cellsCD44 expressionCell line in vitro modelImmune reactivityPancreatic cancer

Related Articles for ""
Eur Surg Res 2012;49:88–98
https://doi.org/10.1159/000341669

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 06, 2012
Accepted: July 05, 2012
Published online: August 30, 2012
Issue release date: October 2012

Number of Print Pages: 11
Number of Figures: 5
Number of Tables: 3

ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)

For additional information: https://www.karger.com/ESR

Abstract

Background: Pancreatic cancer is one of the most deadly malignancies with insufficient therapeutic options and poor outcome. Cancer stem cells (CSCs) are thought to be responsible for progression and therapy resistance. We investigated the potential of pancreatic cell lines for CSC research by analyzing to what extent they contain CSC populations and how representative these are compared to clinical tissue. Methods: Six pancreatic cancer cell lines were analyzed by flow cytometry for CD326, CD133, CD44, CD24, CXCR4 and ABCG2. Subsequently, 70 primary pancreatic tissues were evaluated for CD326, CD133 and CD44 by immunohistochemistry. Results: All the cell lines but one showed a stable expression pattern throughout biological replicates. Marker expression in clinical tissue of CD44 distinguished normal patients from pancreatic carcinoma patients with a sensitivity of 50% at 80% specificity and metastasized from nonmetastasized carcinomas with 69% sensitivity at 100% specificity. Conclusions: Our results indicate a link between elevated CD44 expression, malignancy and metastasis of pancreatic tissue. Furthermore, individual pancreatic cell lines show a substantial amount of cells with CSC properties which is comparable with interpatient variability detected in primary tissue. These pancreatic cancer cell lines could thus serve for urgently needed pharmacological CSC in vitro research.

© 2012 S. Karger AG, Basel



Related Articles:

References

  1. Ghaneh P, Costello E, Neoptolemos JP: Biology and management of pancreatic cancer. Gut 2007;56:1134–1152.
    External Resources
  2. Benson AB 3rd: Adjuvant therapy for pancreatic cancer: one small step forward. JAMA 2007;297:311–313.
    External Resources
  3. Katz MH, Hwang R, Fleming JB, Evans DB: Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008;58:111–125.
    External Resources
  4. Nieto J, Grossbard ML, Kozuch P: Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 2008;13:562–576.
    External Resources
  5. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–2615.
    External Resources
  6. Al-Hajj M, Clarke MF: Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274–7282.
    External Resources
  7. Moserle L, Ghisi M, Amadori A, Indraccolo S: Side population and cancer stem cells: therapeutic implications. Cancer Lett 2009;288:1–9.
    External Resources
  8. Wicha MS: Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 2006;12:5606–5607.
    External Resources
  9. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ: Cancer stem cells: how can we target them? Curr Med Chem 2008;15:3171–3184.
    External Resources
  10. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
    External Resources
  11. Singh SK, Clarke ID, Hide T, Dirks PB: Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267–7273.
    External Resources
  12. Zhong XG, He S, Yin W, Deng JY, Cheng B: Selective tropism of liver stem cells to hepatocellular carcinoma in vivo. World J Gastroenterol 2007;13:3886–3891.
    External Resources
  13. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G: The role of cd133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009;36:446–453.
    External Resources
  14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
    External Resources
  15. O’Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–110.
    External Resources
  16. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328–9337.
    External Resources
  17. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006;103:11154–11159.
    External Resources
  18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–3988.
    External Resources
  19. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–10951.
    External Resources
  20. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104:973–978.
    External Resources
  21. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030–1037.
    External Resources
  22. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H: Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007;6:92–97.
    External Resources
  23. Shipitsin M, Polyak K: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88:459–463.
    External Resources
  24. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX: Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008;14:3903–3907.
    External Resources
  25. Hong SP, Wen J, Bang S, Park S, Song SY: Cd44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009;125:2323–2331.
    External Resources
  26. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313–323.
    External Resources
  27. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A: Expression of the ‘stem cell marker’ CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008;8:48.
    External Resources
  28. Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi H: Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 2007;132:720–732.
    External Resources
  29. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG: Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796–6805.
    External Resources
  30. Locke M, Heywood M, Fawell S, Mackenzie IC: Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005;65:8944–8950.
    External Resources
  31. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638–648.
    External Resources
  32. Han JS, Crowe DL: Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol 2009;34:1449–1453.
    External Resources
  33. van Staveren WC, Solis DY, Hebrant A, Detours V, Dumont JE, Maenhaut C: Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells? Biochim Biophys Acta 2009;1795:92–103.
    External Resources
  34. Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A: Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem 2011;59:441–455.
    External Resources
  35. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, Weitz J: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009;101:457–464.
    External Resources
  36. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719–729.
    External Resources
  37. Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG: Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008;68:7882–7886.
    External Resources
  38. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26:433–446.
    External Resources
  39. Ke XS, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Oyan AM, Kalland KH: Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One 2008;3:e3368.
    External Resources
  40. Seeberger KL, Eshpeter A, Rajotte RV, Korbutt GS: Epithelial cells within the human pancreas do not coexpress mesenchymal antigens: epithelial-mesenchymal transition is an artifact of cell culture. Lab Invest 2009;89:110–121.
    External Resources
  41. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M, Yin Z: Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol 2011;11:71.
    External Resources
  42. Gasparini P, Bertolini G, Binda M, Magnifico A, Albano L, Tortoreto M, Pratesi G, Facchinetti F, Abolafio G, Roz L, Tagliabue E, Daidone MG, Sozzi G: Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Lett 2010;296:206–215.
    External Resources
  43. Yin BB, Wu SJ, Zong HJ, Ma BJ, Cai D: Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. J Zhejiang Univ Sci B 2011;12:256–263.
    External Resources
  44. Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, Wang C: Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci 2011;12:1595–1604.
    External Resources
  45. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527–579.
    External Resources
  46. Jothy S: CD44 and its partners in metastasis. Clin Exp Metastasis 2003;20:195–201.
    External Resources
  47. Gunthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995;24:19–42.
    External Resources
  48. Takada M, Yamamoto M, Saitoh Y: The significance of CD44 in human pancreatic cancer. I. High expression of CD44 in human pancreatic adenocarcinoma. Pancreas 1994;9:748–752.
    External Resources
  49. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zoller M: CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 2009;7:168–179.
    External Resources
  50. Yao J, An Y, Wie JS, Ji ZL, Lu ZP, Wu JL, Jiang KR, Chen P, Xu ZK, Miao Y: Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Med Wkly 2011;141:w13208.
  51. Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D: DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 2008;7:1615–1623.
    External Resources
  52. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA: A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064–6072.
    External Resources
  53. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008;44:823–829.
    External Resources
  54. Shtivelman E, Bishop JM: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;11:5446–5453.
    External Resources
  55. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162–168.
    External Resources
  56. Gao AC, Lou W, Dong JT, Isaacs JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846–849.
    External Resources
  57. Fillmore CM, Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 06, 2012
Accepted: July 05, 2012
Published online: August 30, 2012
Issue release date: October 2012

Number of Print Pages: 11
Number of Figures: 5
Number of Tables: 3

ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)

For additional information: https://www.karger.com/ESR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.49, No. 2

October 2012

Free Supplementary Material

Article

Recommend This
TOP